AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9160360
Drug: Protamine infusion
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine infusion
Trial: 3897895
Drug: Oxiracetam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiracetam (2 X 400 mg capsules t.i.d.)
Trial: 28994705
Drug: Purified anthocyanins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified anthocyanins (320 mg/day)
Trial: 22889987
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training + whey supplement (RW)
Trial: 17442904
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin threshold of 7 g per deciliter)
Trial: 17442904
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin threshold of 9.5 g per deciliter)
Trial: 16181835
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with cisplatin (60 mg/m2 intravenously) and 5-fluorouracil (1,000 mg/m2 per day) for 4 days, three cycles at 3-week intervals
Trial: 12909505
Drug: Premarin, 0.625
RxNorm normalized name: Premarin, 0.625 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin, 0.625 mg for 25 days monthly, with Provera, 10 mg for 10 of these 25 days (hormone therapy) for 2 years
Trial: 9012222
Drug: Golytely solution
DrugBank: Sodium sulfate (DB09472)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Golytely solution (3 litres)
Trial: 6349668
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg once daily for 4 weeks
Trial: 1974505
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg once daily for 4 weeks
Trial: 6349668
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg once daily for 4 weeks
Trial: 6349668
Drug: Atenolol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (all doses)
Trial: 30322501
Drug: Early drain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early drain removal (drains removed output‐based, i.e., flow less than 30 ml/day)
Trial: 22251130
Drug: l-arginine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine (6 g)
Trial: 15086925
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2 g per day
Trial: 8110696
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol 0.1 mg
Trial: 8110696
Drug: Lingual timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lingual timolol 0.1 mg
Trial: 8110696
Drug: Placebo (topical)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (topical)
Trial: 9825366
Drug: Antiarrhythmic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic therapy
Trial: 2483239
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic drugs
Trial: 19189
Drug: Adrenergic bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenergic bronchodilator
Trial: 19189
Drug: Post-adrenergic therapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-adrenergic therapy
Trial: 31567466
Drug: Standard-dose vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose vaccine
Trial: 26406293
Drug: Low AMH
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low AMH (<1.00 ng/mL, n = 124)
Trial: 26406293
Drug: Normal AMH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal AMH (1.00-3.5 ng/mL, n = 595)
Trial: 26406293
Drug: High AMH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High AMH (>3.5 ng/mL, n = 483)
Trial: 23791606
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic cream
Trial: 16961168
Drug: Enteric-coated mycophenolate
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium (180 - 2160 mg)
Trial: 16961168
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (not specified dosage)
Trial: 15625835
Drug: Holothuria Ldeucospilota
RxNorm normalized name: Holothuria sea cucumber preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holothuria Ldeucospilota Acidic Mucopolysaccharide (HLAM) 60 mg/d
Trial: 15625835
Drug: Holothuria Ldeucospilota
RxNorm normalized name: Holothuria sea cucumber preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holothuria Ldeucospilota Acidic Mucopolysaccharide (HLAM) 120 mg/d
Trial: 23296097
Drug: Tacrolimus modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus modified-release once-daily preparation (Advagraf, Graceptor)
Trial: 2942806
Drug: Fenoterol/ipratropium combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol/ipratropium combination (100 micrograms fenoterol and 40 micrograms ipratropium bromide per puff, 2 puffs)
Trial: 28007133
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg once daily for 5 years
Trial: 25876338
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of acupuncture and tapping method
Trial: 3293872
Drug: Tyramine administered
RxNorm normalized name: tyramine
DrugBank: Tyramine (DB08841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyramine administered by bolus injection
Trial: 3293872
Drug: Tyramine administered
RxNorm normalized name: tyramine
DrugBank: Tyramine (DB08841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyramine administered by infusion
Trial: 23758078
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus weekly/biweekly teleconsultations with an endocrinologist (n=12)
Trial: 21478777
Drug: Telephone-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered cognitive behavioral therapy (CBT) plus pedometer-based walking program
Trial: 18855558
Drug: Nonadjuvanted RSV
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadjuvanted RSV vaccine
Trial: 18855558
Drug: RSV vaccine
RxNorm normalized name: RSV VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV vaccine (both formulations)
Trial: 16861098
Drug: Propacetamol 30
RxNorm normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 30 mg/kg IV
Trial: 12911355
Drug: Oral flexible
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral flexible intubating fibrescope
Trial: 8130009
Drug: Low-molecular-heparin (Sandoparin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-heparin (Sandoparin)
Trial: 8130009
Drug: Standard-heparin (Liquemin:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-heparin (Liquemin: 3 x 5000 I.E.)
Trial: 8130009
Drug: Standard-heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-heparin
Trial: 8130009
Drug: Low-molecular-heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-heparin
Trial: 27249781
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg LSD
Trial: 20117912
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.1 mg (group M)
Trial: 11149624
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (1.5 mU/kg x min)
Trial: 11149624
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (saline solution)
Trial: 4048899
Drug: Magaldrate tablets
RxNorm normalized name: Magaldrate Tablets
DrugBank: Magaldrate (DB08938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magaldrate tablets
Trial: 4048899
Drug: Al-Mg-hydroxide tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al-Mg-hydroxide tablets
Trial: 4048899
Drug: Al-Mg-hydroxide liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al-Mg-hydroxide liquid
Trial: 27063928
Drug: AZP-531 15
RxNorm normalized name: Azp-2006 free base
DrugBank: Ezeprogind (DB16954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZP-531 15 µg/kg or higher
Trial: 27063928
Drug: AZP-531 60
RxNorm normalized name: Azp-2006 free base
DrugBank: Ezeprogind (DB16954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZP-531 60 µg/kg
Trial: 24866968
Drug: Dynamic supportive‐expressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic supportive‐expressive therapy
Trial: 24866968
Drug: Supportive clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive clinical management combined with pharmacotherapy or placebo
Trial: 20822968
Drug: 50 µg/m³
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg/m³ elemental carbon UFP for 2 hr
Trial: 17937474
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 to 10 mg/kg) plus methotrexate (MTX)
Trial: 7610357
Drug: Pancreatic extract
RxNorm normalized name: Pancreatic extract pancrelipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic extract (Pancrex-Duo capsules, 34,375 USP units of protease, 4 capsules four times daily for 4 months)
Trial: 7610357
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 capsules four times daily for 4 months)
Trial: 2118307
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 320/1,600 mg daily
Trial: 2118307
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 160/800 mg daily
Trial: 215307
Drug: Thymosin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin at a dose of 60 mg/m2
Trial: 215307
Drug: Thymosin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin at a dose of 20 mg/m2
Trial: 28618724
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 mg/BD/IM)
Trial: 23588235
Drug: Lactulose 25
RxNorm normalized name: lactulose 2500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose 25 g
Trial: 19513632
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (o.d.) dosing of insulin detemir
Trial: 19513632
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (b.i.d.) dosing of insulin detemir
Trial: 19513632
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from o.d. to b.i.d. dosing
Trial: 16426286
Drug: Barrier cream
RxNorm normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Barrier cream containing vaseline
Trial: 16426286
Drug: Barrier cream
RxNorm normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Barrier cream containing bees wax
Trial: 16426286
Drug: Barrier cream
RxNorm normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Barrier cream containing waxes and surfactant
Trial: 16426286
Drug: No barrier
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No barrier cream (control)
Trial: 12877903
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg/day for 4 weeks
Trial: 8818851
Drug: Co-amoxiclav (37
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (37 mg three times daily for 10 days)
Trial: 28750695
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg twice daily + low-dose aspirin (ASA)
Trial: 28750695
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg twice daily + low-dose ASA
Trial: 28750695
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + low-dose aspirin (ASA)
Trial: 19406232
Drug: Lyophilized orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized orally disintegrating tablets (ODTs) of nimesulide (100mg)
Trial: 19406232
Drug: Conventional immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immediate release tablet (Sulide)
Trial: 11134193
Drug: Doxorubicin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (n = 637, median total dose of 294 mg/m(2))
Trial: 7956752
Drug: Resumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resumption of treatment during follow-up
Trial: 2837046
Drug: Indomethacin 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 1% ophthalmic solution (one drop the evening before surgery and one drop 45 minutes before surgery)
Trial: 27733560
Drug: Inhaled CVT‐301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled CVT‐301 (50 mg)
Trial: 27733560
Drug: Oral carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbidopa/levodopa (25 mg/100 mg)
Trial: 23347336
Drug: Preoperatively 2
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperatively 2 g of amoxycillin 1 h before surgery (positive control, PC)
Trial: 23347336
Drug: Postoperatively 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperatively 2 g of amoxycillin immediately following surgery (test 1, T1)
Trial: 23347336
Drug: Preoperatively 2
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperatively 2 g of amoxycillin 1 h before and 500 mg thrice daily on days 2 and 3 after surgery (test 2, T2)
Trial: 23347336
Drug: Preoperatively 2
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperatively 2 g of placebo 1 h before surgery (negative control, NC)
Trial: 18299694
Drug: General measurements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General measurements (low dose and short period of glucocorticoids)
Trial: 16805710
Drug: Platinum-based adjuvant
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based adjuvant therapy in patients with resected stage IB and II NSCLC
Trial: 16805710
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy in resected stage III NSCLC
Trial: 11061252
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (low-dose lorazepam)
Trial: 3615347
Drug: Clovoxamine 50
RxNorm normalized name: fluvoxamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clovoxamine 50 mg, 100 mg, 150 mg
Trial: 7341285
Drug: Mianserin 20
RxNorm normalized name: mianserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 20 mg
Trial: 26724489
Drug: Elevated baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated baseline BNP (> median = 72 ng/L)
Trial: 31425658
Drug: Tinnitus Retraining
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus Retraining Therapy (TRT)
Trial: 25319676
Drug: TRT counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRT counseling and sound therapy
Trial: 15358440
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (rhGH, Somatropin) replacement therapy for 6 months (Group I)
Trial: 15358440
Drug: Open study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open study design with GH treatment for 6 months (Group II)
Trial: 9582849
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy (two daily injections of a mixture of regular insulin/NPH)
Trial: 7609279
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (0.15 mg of Somatropin per kilogram per day)
Trial: 8189476
Drug: Vehicle of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of infusion (Control)
Trial: 1977781
Drug: Terfenadine, 60
RxNorm normalized name: Terfenadine, 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine, 60 mg
Trial: 1977781
Drug: Chlorpheniramine, 4
RxNorm normalized name: Chlorpheniramine, 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine, 4 mg
Trial: 416322
Drug: Clofibate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate (1 g b.i.d.)
Trial: 416322
Drug: Lactose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose placebo (1 g b.i.d.)
Trial: 30567286
Drug: Moderate intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate intake of total LC ω‐3 PUFA (approximately 0.5⁻1 g/day)
Trial: 20537722
Drug: Manual Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Assisted Cognitive Therapy (MACT)
Trial: 20537722
Drug: Manual Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Assisted Cognitive Therapy (MACT) + Therapeutic Assessment (TA)
Trial: 30806492
Drug: Standard Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Behavioral Treatment (SBT)
Trial: 7552878
Drug: Cyclosporine rinse
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine rinse (5 ml, 500 mg)
Trial: 7552878
Drug: Placebo rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rinse (5 ml)
Trial: 2147909
Drug: Doxazosin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (mean dose 11 mg) + Atenolol (100 mg)
Trial: 2147909
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg) + Placebo
Trial: 26099195
Drug: Zn alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zn alone group (30 mg ZnSO4 daily)
Trial: 26099195
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (30 mg ZnSO4 plus multivitamins)
Trial: 26099195
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo, 270 mg lactose)
Trial: 21410693
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (15 minutes of daily bimanual training with a mirror for 3 weeks)
Trial: 21410693
Drug: Bimanual training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimanual training without a mirror (15 minutes daily for 3 weeks)
Trial: 19281729
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral topotecan formulation (4 mg dose)
Trial: 19281729
Drug: Current oral
RxNorm normalized name: black currant oil Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current oral topotecan formulation (4 mg dose)
Trial: 19281729
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral topotecan formulation (4 mg dose) in fed state
Trial: 19281729
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral topotecan formulation (4 mg dose) in fasted state
Trial: 15547701
Drug: oral doxifluridine
RxNorm normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral doxifluridine
Trial: 15547701
Drug: intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of 5-FU
Trial: 15547701
Drug: intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of irinotecan
Trial: 15547701
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of doxifluridine and irinotecan
Trial: 2845349
Drug: RRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV vaccine (10^4 plaque-forming units)